Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

Core Insights - Acadia Pharmaceuticals Inc. announced the publication of interim results from the LOTUS study, which evaluates the effectiveness and tolerability of DAYBUE® (trofinetide) in patients with Rett syndrome [1] Group 1: Study Findings - The LOTUS study is an observational online, open-label study that focuses on caregiver-reported outcomes [1] - Findings indicate reported improvements in symptoms of Rett syndrome among patients prescribed DAYBUE® under routine clinical care in the U.S. [1]